Acusphere, Inc is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. Acusphere, Inc is focused on developing proprietary drugs that can offer significant benefits over existing drugs, including improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost. The Company’s lead product candidate Imagify™ (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700) is a cardiovascular drug is in development for the detection of coronary artery disease. Acusphere, Inc also has demonstrated that its technology has the potential to improve the formulation of hydrophobic drugs and asthma drugs.